Three-year data from the ALLEGRO-2b/3 long-term extension, presented at EADV 2025, showed about 90% of patients who reached SALT score <=20 at 12 months maintained that response through 3 years, with roughly 30% achieving complete scalp regrowth; separate analyses reported reduced psychosocial burden by week 48 at the 50 mg dose.
- Lab
- Phase 1
- Phase 2
- Phase 3
- Approved
Approved (some countries)
How it works
Oral JAK3/TEC family kinase inhibitor that blocks signalling pathways involved in the immune attack on hair follicles in alopecia areata.
Results so far
65.1% of patients maintained SALT score <=20 at 36-38 months; of those who hit that threshold at 12 months, ~90% sustained it to 3 years.
What's next
Already approved in the US; long-term-extension data continuing to read out through 2025-2026. No specific India regulatory timeline found.
In India
No CDSCO approval or Indian launch/trial found in this research pass.
Sources
- News report ↗ (accessed 2026-10-17)
- News report ↗ (accessed 2026-10-17)
- Journal paper ↗ (accessed 2026-10-17)
- Journal paper ↗ (accessed 2026-10-17)
What to do today: treatments in development aren't a reason to wait. Ask a dermatologist about the options that work now, such as minoxidil, or see alopecia areata treatments.
Discussion
Share your experience or ask a question. New members' posts are reviewed before they appear.